TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21532740

Group type: EXPERIMENTAL
Intervention: Kato-Katz method
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: FLOTAC method
Number of subjects: 343
Study: 19478341

Group type: EXPERIMENTAL
Intervention: High-impact and resistance-training exercise (EX)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Restricted physical activity (NE)
Number of subjects: 10
Study: 17299194

Group type: EXPERIMENTAL
Intervention: Routine upstream Gp IIb/IIIa inhibitor administration (n=4605)
Number of subjects: 9207

Group type: COMPARATOR
Intervention: Deferred selective Gp IIb/IIIa inhibitor administration (n=4602)
Number of subjects: 9207
Study: 15685831

Group type: EXPERIMENTAL
Intervention: Irinotecan combined with 5-FU/leucovorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-FU/leucovorin alone
Number of subjects: 0
Study: 11675948

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2.7 g/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9637582

Group type: EXPERIMENTAL
Intervention: Recruitment methods and participant motivations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recruitment and screening processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood donation and willingness to be contacted by phone
Number of subjects: 0
Study: 7727280

Group type: EXPERIMENTAL
Intervention: Cysteine 500 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2690871

Group type: EXPERIMENTAL
Intervention: 0.3 ppm nitrogen dioxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 60
Study: 31507250

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with integrated exposure and emotion-focused elements (CBT-EE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both CBT and CBT-EE
Number of subjects: 0
Study: 30266529

Group type: EXPERIMENTAL
Intervention: Ofloxacin drops (OFLX)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gelatin sponge patches
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spontaneous healing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Endoscopic myringoplasty
Number of subjects: 100
Study: 28277996

Group type: EXPERIMENTAL
Intervention: Electric stimulation therapy (EST) used 4 times daily for 20 minutes per session.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham device (control group) used 4 times daily for 20 minutes per session.
Number of subjects: 23
Study: 25460259

Group type: EXPERIMENTAL
Intervention: Fear reactivation using a virtual spider 10 min prior to VR exposure (reactivation group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group exposed to a virtual plant 10 min prior to VR exposure
Number of subjects: 32
Study: 23623506

Group type: EXPERIMENTAL
Intervention: FTCQ‐12 risk score (RS; Factor 2, Expectancy plus Factor 4, Purposefulness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MNWS craving
Number of subjects: 0
Study: 21804463

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg/day for 18 months)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bisphosphonates (70 mg/week for 18 months)
Number of subjects: 2
Study: 19333933

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16422446

Group type: EXPERIMENTAL
Intervention: Strobe light (4 Hz stroboscopic illumination)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LCD shutter glasses (4 Hz stroboscopic illumination)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal room illumination (control condition)
Number of subjects: 32
Study: 15297775

Group type: EXPERIMENTAL
Intervention: Isotonic polyethylene glycol solution containing 50 microCi of [51Cr]EDTA administered through a nasoduodenal tube for intestinal lavage
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Histamine and ECP concentrations
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intestinal permeability assessment by 5-hour urinary excretion of [51Cr]EDTA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Calprotectin analysis in native faecal samples
Number of subjects: 52
Study: 11408434

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (75%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Extra energy + high carbohydrate diet (CHO + E)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Habitual diet (Hab)
Number of subjects: 12
Study: 10771859

Group type: EXPERIMENTAL
Intervention: Preterm milk
Number of subjects: 52

Group type: COMPARATOR
Intervention: Term milk
Number of subjects: 52
Study: 1722511

Group type: EXPERIMENTAL
Intervention: Columbia 13-14 curet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: P-10 ultrasonic instrument
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diamond-coated P-10 ultrasonic instrument
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Antiformin/citric acid chemical treatment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 90
Study: 6181560

Group type: EXPERIMENTAL
Intervention: Transvesical prostatectomy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Transurethral prostatectomy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Prostatectomy (in patients with upper urinary tract obstruction)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Prostatectomy (in patients with normal upper urinary tract)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Total patient group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Patients with renographic obstruction preoperatively
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Preoperative patients with upper urinary tract obstruction
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Preoperative patients with normal urography
Number of subjects: 59
Study: 31475794

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Number of subjects: 4822

Group type: COMPARATOR
Intervention: Valsartan (target dose, 160 mg twice daily)
Number of subjects: 4822
Study: 29137512

Group type: EXPERIMENTAL
Intervention: Micronutrient powders distributed at microfinance meetings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 27680994

Group type: EXPERIMENTAL
Intervention: Counseling plus 1 of 4 complementary food supplements (CFSs) fed as a daily snack
Number of subjects: 5499

Group type: COMPARATOR
Intervention: Control group (periodic child feeding counseling for mothers)
Number of subjects: 5499

Group type: EXPERIMENTAL
Intervention: Counseling plus CFSs
Number of subjects: 5499
Study: 24026156

Group type: EXPERIMENTAL
Intervention: Cervical microendoscopic discectomy and fusion (CMEDF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 70
Study: 20974542

Group type: EXPERIMENTAL
Intervention: Simulator-based teaching session (90 minutes)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional training (books, articles, web-based resources)
Number of subjects: 2
Study: 19934822

Group type: EXPERIMENTAL
Intervention: ketorolac 0.4% 4 times a day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: bromfenac 0.09% 2 times a day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: nepafenac 0.1% 3 times a day
Number of subjects: 31

Group type: COMPARATOR
Intervention: no NSAID
Number of subjects: 31
Study: 17096178

Group type: EXPERIMENTAL
Intervention: 0.25 percent glycerin trinitrate ointment and cryothermal anal dilators
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.25 percent glycerin trinitrate ointment only
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cryothermal anal dilators only
Number of subjects: 48
Study: 15011418

Group type: EXPERIMENTAL
Intervention: Olprinone hydrochloride (15 micrograms.kg‐1 bolus plus 0.1 microgram.kg‐1.min‐1 continuous administration)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no olprinone hydrochloride)
Number of subjects: 56
Study: 11710410

Group type: EXPERIMENTAL
Intervention: Weight Belt (WB)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No Weight Belt (NWB)
Number of subjects: 14
Study: 9536857

Group type: EXPERIMENTAL
Intervention: Black tea (6 mugs per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 7801664

Group type: EXPERIMENTAL
Intervention: Iomeprol 350 (IO)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Diatrizoate 370 (DIA)
Number of subjects: 49
Study: 3197370

Group type: EXPERIMENTAL
Intervention: Angiotensin II (1 pmol/min)
Number of subjects: 14
Study: 31871055

Group type: EXPERIMENTAL
Intervention: Faecal volatile organic compounds (VOCs) associated with NEC
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Individual VOCs identified through discriminant analyses
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Faecal VOCs in NEC cases
Number of subjects: 1326
Study: 29016943

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev) added to radiotherapy/temozolomide
Number of subjects: 621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study: 28302179

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids (clinician's choice of lactated Ringer's solution or Plasma‐Lyte A®)
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride)
Number of subjects: 14000

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 14000
Study: 26140401

Group type: EXPERIMENTAL
Intervention: Strong opioids (oxycodone/morphine/meperidine)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Weak opioids (codeine/propoxyphene/hydrocodone)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Opioid-naïve
Number of subjects: 1004
Study: 24171779

Group type: EXPERIMENTAL
Intervention: Chungkookjang (35 g daily for 12 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20484620

Group type: EXPERIMENTAL
Intervention: Oral clonidine, 1.5 µg/kg every 4 hours starting the second week of life
Number of subjects: 36
Study: 18332051

Group type: EXPERIMENTAL
Intervention: Single dose of rifampicin
Number of subjects: 21711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21711
Study: 16997001

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 14517773

Group type: EXPERIMENTAL
Intervention: Synthetic GLP-1 (7-36 amide) at 1.2 pmol/kg/min administered over a period of three hours during glucose injection.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administered during the fasting state.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 administered until 120 or 30 min before the glucose load.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 administered until -30 min before glucose load.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-1 administration during glucose injection.
Number of subjects: 8
Study: 10929918

Group type: EXPERIMENTAL
Intervention: Metformin 1,700 mg/d
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8938531

Group type: EXPERIMENTAL
Intervention: alpha-interferon treatment
Number of subjects: 100
Study: 8421087

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg, twice daily for 7 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3570479

Group type: EXPERIMENTAL
Intervention: Fusidic acid 1% eye preparation, given four to six times daily for one week
Number of subjects: 248

Group type: COMPARATOR
Intervention: Chloramphenicol 0.5% eye drops, given four to six times daily for one week
Number of subjects: 248
Study: 29226818

Group type: EXPERIMENTAL
Intervention: Tailored pacemaker rate‐response programming based on the force-frequency relationship (FFR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional rate‐response programming
Number of subjects: 90
Study: 27402466

Group type: EXPERIMENTAL
Intervention: Laser (L)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Laser with topical antifungal therapy (L + T)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Topical antifungal treatment (T)
Number of subjects: 56
Study: 25276082

Group type: EXPERIMENTAL
Intervention: bimatoprost (0.03%)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: latanoprost (0.005%)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: travoprost (0.004%)
Number of subjects: 140

Group type: COMPARATOR
Intervention: timolol (0.5%)
Number of subjects: 140
Study: 23957382

Group type: EXPERIMENTAL
Intervention: Continuous CSF drainage with intermittent ICP monitoring (open‐EVD group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous ICP monitoring with intermittent CSF drainage (monitor‐ICP group)
Number of subjects: 60
Study: 21357642

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 0
Study: 18755458

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 198

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 198
Study: 17161051

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF) at 5 to 10 microg/kg per day subcutaneously for 5 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF) at 5 microg/kg per day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF) at 10 microg/kg per day
Number of subjects: 18
Study: 14576541

Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Soft Seal LM
Number of subjects: 200
Study: 10933738

Group type: EXPERIMENTAL
Intervention: Suture repair
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mesh repair
Number of subjects: 200
Study: 8718436

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/day p.o.)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 1524753

Group type: EXPERIMENTAL
Intervention: Modified Kapur scale
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Kapur scale
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two denture adhesives
Number of subjects: 0
Study: 6202090

Group type: EXPERIMENTAL
Intervention: Dacriosol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isopto Plain
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 31121394

Group type: EXPERIMENTAL
Intervention: Silexan (80 mg/day)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 29189308

Group type: EXPERIMENTAL
Intervention: Lactotripeptides (4.5 mg/d, thrice on exercise day and day after)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (4.5 mg/d, thrice on exercise day and day after)
Number of subjects: 22
Study: 27050069

Group type: EXPERIMENTAL
Intervention: Diabetes-specific oral nutritional supplement (ONS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isocaloric standard ONS (control)
Number of subjects: 40
Study: 24314909

Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Repetitive TMS (rTMS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham interventions
Number of subjects: 18
Study: 23979567

Group type: EXPERIMENTAL
Intervention: Optical frequency domain imaging (OFDI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (no intervention on identified FS)
Number of subjects: 97
Study: 20795384

Group type: EXPERIMENTAL
Intervention: Pneumo 23 and Act-HIB vaccines
Number of subjects: 256
Study: 18463424

Group type: EXPERIMENTAL
Intervention: Topical Visthesia drops
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (Healon)
Number of subjects: 18
Study: 15962453

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) daily
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) alternate days
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 12756509

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (normolipidemic participants)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 54
Study: 10048647

Group type: EXPERIMENTAL
Intervention: Microultrasonic inserts (Slimline FSI left and right‐Dentsply)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conventional ultrasonic insert (P10 insert‐Dentsply)
Number of subjects: 30
Study: 8622103

Group type: EXPERIMENTAL
Intervention: isepamicin (15 mg/kg once daily)
Number of subjects: 267

Group type: COMPARATOR
Intervention: amikacin (7.5 mg/kg twice daily)
Number of subjects: 267
Study: 2265155

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with epinephrine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with epinephrine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.0% with epinephrine
Number of subjects: 46
Study: 728895

Group type: EXPERIMENTAL
Intervention: Levamisole (doses ranged from 65 to 410 mg/m2, maximum tolerated dose 358 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 31309239

Group type: EXPERIMENTAL
Intervention: Teriparatide + WBV
Number of subjects: 35

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 35
Study: 29055242

Group type: EXPERIMENTAL
Intervention: Task‐oriented Functional Training (TFT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Wii training
Number of subjects: 43
Study: 26241598

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (n=242)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Assessed control (n=237)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No-contact control (n=121)
Number of subjects: 600
Study: 23895296

Group type: EXPERIMENTAL
Intervention: Reduced toxicant prototype (RTP) cigarette (7 mg ISO tar yield)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial cigarettes
Number of subjects: 0
Study: 21320198

Group type: EXPERIMENTAL
Intervention: Group A (anti-hypertensive education)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group B (anti-hypertensive education + healthy lifestyle education)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (routine monitoring)
Number of subjects: 120
Study: 18653687

Group type: EXPERIMENTAL
Intervention: 4D Flow MR imaging
Number of subjects: 0
Study: 16984498

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg s.c.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study: 14962329

Group type: EXPERIMENTAL
Intervention: Propofol (200 microg.kg(‐1).min(‐1))
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sevoflurane (1.5‐2.5%)
Number of subjects: 56
Study: 10924726

Group type: EXPERIMENTAL
Intervention: DSA (dextran sulphate adsorption)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IMAL (immunoadsorption)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: DALI (direct adsorption of lipoproteins)
Number of subjects: 8
Study: 9066740

Group type: EXPERIMENTAL
Intervention: Peri-operative adjuvant chemotherapy (PAC) with CEF (cyclophosphamide 600 mg/sqm, epidoxorubicin 60 mg/sqm, 5-fluorouracil 600 mg/sqm)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (no PAC)
Number of subjects: 375
Study: 8394470

Group type: EXPERIMENTAL
Intervention: Priming with 10% of total dose (T) of pipecuronium
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Priming with 5%, 15%, or 20% of total dose (T) of pipecuronium
Number of subjects: 52

Group type: COMPARATOR
Intervention: No priming
Number of subjects: 52
Study: 3523393

Group type: EXPERIMENTAL
Intervention: Transdermal iontophoresis of vincristine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 29174864

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20-40mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 26859610

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 133
Study: 24950841

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 360
Study: 22129564

Group type: EXPERIMENTAL
Intervention: Intensity-modulated proton therapy (IMPT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Passive scattering proton therapy (PSPT)
Number of subjects: 16
Study: 20925201

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6 mg/kg body weight
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) and Albendazole
Number of subjects: 54
Study: 18789649

Group type: EXPERIMENTAL
Intervention: Protein- and energy-enriched diet and snacks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard food of the nursing home
Number of subjects: 65
Study: 15549326

Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/day for 6 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12416663

Group type: EXPERIMENTAL
Intervention: Cardiovascular and strength programme (CSP)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise programme (CEP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Baseline exercise programme (BEP)
Number of subjects: 96
Study: 10333947

Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8975299

Group type: EXPERIMENTAL
Intervention: FSE-CHESS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: STIR-FSE
Number of subjects: 32

Group type: COMPARATOR
Intervention: T1-weighted SE
Number of subjects: 32